Skip to content
Head to head

Amneal Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: AMRX · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

AMRX +82.4%TAK +56.6%
Amneal Pharmaceuticals edges it on the scoreable measures. Amneal Pharmaceuticals has the highest Quant Rating (96); Amneal Pharmaceuticals has done best over the past year (+83%); Amneal Pharmaceuticals trades cheapest on trailing earnings.
AMRXTAK
Snapshot
Sector----
Last price21.1221.77
Change today-1.26%+1.68%
1-year return+83.4%+57.5%
Market cap$7.36B$69.76B
52-week range11.71 – 22.1313.92 – 22.07
Valuation
P/E (TTM)52.80311.00
P/E percentile, own 5-yr range69th100th
P/B13.851.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.22-0.30
Net profit (TTM)$76.65M$-970.94M
Revenue (TTM)$3.20B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+10.0%+6.7%
Gross margin40.2%65.8%
Operating margin16.7%14.3%
Net margin4.2%0.9%
Free cash flow (TTM)$-61.18M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership49.6%51.3%
Insider activity (12mo)35 buy / 15 sell19 buy / 31 sell
Short interest (% of float)3.6%0.1%
Analyst consensus100% buy (5)100% buy (1)
Analyst price target$24 (+16%)$50 (+132%)
StockVane view
StockVane Quant RatingC (96)C (90)
Company
Employees8,50047,029
Founded20021781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.